Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association

May 14, 2024

https://www.globenewswire.com/news-release/2024/05/14/2881560/0/en/Keros-Therapeutics-to-Present-at-the-29th-Annual-Congress-of-the-European-Hematology-Association.html

LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that five abstracts will be presented from the KER-050 (elritercept) program at the 29th Annual Congress of the European Hematology Association (“EHA”), to be held both virtually and in person from June 13 through 16, 2024.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.